Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 9/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087891 | 0.82 | GRM4 (0.70) | GRM4HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL27177146 | 0.80 | BCAT2 (0.63) | KDRKCNK3KCNK9SMN1; SMN2NPC1 | |
| SCHEMBL3099628 | 0.80 | NPC1 (0.65) | GRM4HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL944037 | 0.80 | BCAT2 (0.62) | GRM4HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL20524660 | 0.79 | GRM4 (0.71) | GRM4HDAC6KDRKCNK3KCNK9 | |
| SCHEMBL30323190 | 0.79 | GRM4 (0.71) | GRM4HDAC6KDRKCNK3KCNK9 | |
| SCHEMBL12469188 | 0.78 | ATG4B (0.69) | GRM4HDAC6KDRKCNK3KCNK9 | |
| SCHEMBL6925149 | 0.77 | GRM5 (0.74) | GRM4SMN1; SMN2NPC1RAB9APKM | |
| SCHEMBL29581099 | 0.76 | NPC1 (0.64) | GRM4HDAC6KDRKCNK3KCNK9 | |
| SCHEMBL12469044 | 0.76 | NPC1 (0.64) | GRM4HDAC6KDRKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335512-A2 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HiberCell, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11535635-B2 | — | — | 2022-12-27 | — | — | US | disclosed |
| US-11535635-B2 | — | — | 2022-12-27 | — | — | US | disclosed |
| US-20210253600-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210253600-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2021-08-19 | — | — | US | disclosed |
| CN-111936484-A | Chromenopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase | 拉文纳制药公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-3728217-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PI4KA | GRM4 821/4885HDAC6 2934/4885HDAC3 1202/4885 |
| US-11535635-B2 | — | PIP5K1A, PI4K2A, PIP5K1B | GRM4 1230/4885HDAC6 1079/4885HDAC3 833/4885 |
| US-20210253600-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PI4KA | GRM4 821/4885HDAC6 2934/4885HDAC3 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.